| scholarly article | Q13442814 |
| P50 | author | Christian Haass | Q107652 |
| Peer-Hendrik Kuhn | Q37381680 | ||
| Dieter Edbauer | Q63092229 | ||
| Anja Capell | Q63092243 | ||
| P2093 | author name string | Elisabeth Kremmer | |
| Katrin Fellerer | |||
| Benjamin M Schwenk | |||
| Christina M Lang | |||
| P2860 | cites work | Loss of progranulin function in frontotemporal lobar degeneration | Q37105126 |
| ESCRT functions in autophagy and associated disease | Q37140414 | ||
| Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members | Q37148011 | ||
| Sorting of lysosomal proteins | Q37338623 | ||
| Molecular characterization of novel progranulin (GRN) mutations in frontotemporal dementia | Q37373937 | ||
| Pathogenic cysteine mutations affect progranulin function and production of mature granulins | Q39760142 | ||
| Low plasma progranulin levels predict progranulin mutations in frontotemporal lobar degeneration. | Q40051471 | ||
| CHMP2B C-truncating mutations in frontotemporal lobar degeneration are associated with an aberrant endosomal phenotype in vitro | Q40063451 | ||
| Rescue of progranulin deficiency associated with frontotemporal lobar degeneration by alkalizing reagents and inhibition of vacuolar ATPase. | Q41933726 | ||
| Frontotemporal lobar degeneration genome wide association study replication confirms a risk locus shared with amyotrophic lateral sclerosis | Q42687225 | ||
| Progranulin plasma levels in the diagnosis of frontotemporal dementia | Q42721059 | ||
| Serum biomarker for progranulin-associated frontotemporal lobar degeneration | Q46087404 | ||
| Genetic variability in progranulin contributes to risk for clinically diagnosed Alzheimer disease | Q46813677 | ||
| Mutations other than null mutations producing a pathogenic loss of progranulin in frontotemporal dementia | Q48250357 | ||
| Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. | Q51970665 | ||
| Clinical, genetic, and pathologic characteristics of patients with frontotemporal dementia and progranulin mutations. | Q51972686 | ||
| Missense mutations in the progranulin gene linked to frontotemporal lobar degeneration with ubiquitin-immunoreactive inclusions reduce progranulin production and secretion. | Q51973117 | ||
| Frontotemporal dementia. | Q53577166 | ||
| Granulin mutations associated with frontotemporal lobar degeneration and related disorders: an update | Q81430169 | ||
| Immunoprecipitation | Q94698516 | ||
| Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia | Q24309521 | ||
| Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia | Q24600027 | ||
| A new subtype of frontotemporal lobar degeneration with FUS pathology | Q24647697 | ||
| Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21 | Q28253639 | ||
| Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 | Q28253651 | ||
| The roles of intracellular protein-degradation pathways in neurodegeneration | Q28269322 | ||
| Lysosomal proteolysis and autophagy require presenilin 1 and are disrupted by Alzheimer-related PS1 mutations | Q28506710 | ||
| Isolation of intracellular membranes by means of sodium carbonate treatment: application to endoplasmic reticulum | Q29547483 | ||
| Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria | Q29614410 | ||
| Rab conversion as a mechanism of progression from early to late endosomes | Q29616151 | ||
| Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein | Q29619232 | ||
| Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions | Q30434949 | ||
| Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration | Q33685317 | ||
| Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations | Q33832871 | ||
| FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration | Q33922335 | ||
| Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration | Q33999208 | ||
| Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update | Q34020227 | ||
| Sortilin-mediated endocytosis determines levels of the frontotemporal dementia protein, progranulin. | Q34346014 | ||
| CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines. | Q34454439 | ||
| TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers. | Q34555400 | ||
| TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort | Q34605483 | ||
| Association of TMEM106B gene polymorphism with age at onset in granulin mutation carriers and plasma granulin protein levels | Q34959322 | ||
| The neuropathogenic contributions of lysosomal dysfunction | Q34975994 | ||
| Autophagy failure in Alzheimer's disease--locating the primary defect | Q34987827 | ||
| Lysosome biogenesis and lysosomal membrane proteins: trafficking meets function | Q34996827 | ||
| TMEM106B a novel risk factor for frontotemporal lobar degeneration | Q35512313 | ||
| Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. | Q35587208 | ||
| Lysosomal proteolysis inhibition selectively disrupts axonal transport of degradative organelles and causes an Alzheimer's-like axonal dystrophy | Q35955959 | ||
| Functional multivesicular bodies are required for autophagic clearance of protein aggregates associated with neurodegenerative disease | Q36119653 | ||
| Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes | Q36227050 | ||
| The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments | Q36931728 | ||
| Roles of ESCRT in autophagy-associated neurodegeneration | Q37038296 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | risk factor | Q1475848 |
| frontotemporal lobar degeneration | Q18579 | ||
| transmembrane protein | Q424204 | ||
| P304 | page(s) | 19355-19365 | |
| P577 | publication date | 2012-04-17 | |
| P1433 | published in | Journal of Biological Chemistry | Q867727 |
| P1476 | title | Membrane orientation and subcellular localization of transmembrane protein 106B (TMEM106B), a major risk factor for frontotemporal lobar degeneration | |
| P478 | volume | 287 |
| Q38841003 | "New Old Pathologies": AD, PART, and Cerebral Age-Related TDP-43 With Sclerosis (CARTS). |
| Q47620193 | A Dementia-Associated Risk Variant near TMEM106B Alters Chromatin Architecture and Gene Expression. |
| Q99233874 | A molecular sensor to quantify the localization of proteins, DNA and nanoparticles in cells |
| Q36070145 | A novel Alzheimer disease locus located near the gene encoding tau protein. |
| Q46317492 | A recurrent de novo mutation in TMEM106B causes hypomyelinating leukodystrophy |
| Q36910788 | An extended proteome map of the lysosomal membrane reveals novel potential transporters |
| Q37609848 | Elevated TMEM106B levels exaggerate lipofuscin accumulation and lysosomal dysfunction in aged mice with progranulin deficiency |
| Q37485507 | Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain |
| Q59800165 | Frontotemporal dementia causative CHMP2B impairs neuronal endolysosomal traffic-rescue by TMEM106B knockdown |
| Q36073666 | Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology |
| Q89438455 | Genetic Modifiers in Neurodegeneration |
| Q38786774 | Genetics of FTLD: overview and what else we can expect from genetic studies |
| Q34658391 | Genome-wide association studies in neurology |
| Q37530270 | Increased expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent alterations in lysosomes |
| Q48187381 | Loss of TMEM106B Ameliorates Lysosomal and Frontotemporal Dementia-Related Phenotypes in Progranulin-Deficient Mice. |
| Q99420895 | Loss of TMEM106B potentiates lysosomal and FTLD-like pathology in progranulin-deficient mice |
| Q55209391 | Loss of Tmem106b is unable to ameliorate frontotemporal dementia-like phenotypes in an AAV mouse model of C9ORF72-repeat induced toxicity. |
| Q91747205 | Lysosomal size matters |
| Q92402726 | Lysosomal targeting of the ABC transporter TAPL is determined by membrane-localized charged residues |
| Q28585799 | Lysosome size, motility and stress response regulated by fronto-temporal dementia modifier TMEM106B |
| Q26824221 | Mechanisms of granulin deficiency: lessons from cellular and animal models |
| Q39035458 | Molecular Genetics of Neurodegenerative Dementias |
| Q39428501 | Multifaceted role of SMCR8 as autophagy regulator. |
| Q37359314 | Progranulin promotes peripheral nerve regeneration and reinnervation: role of notch signaling |
| Q47623958 | Progranulin: a new avenue towards the understanding and treatment of neurodegenerative disease |
| Q36078240 | Prosaposin facilitates sortilin-independent lysosomal trafficking of progranulin |
| Q41700803 | Quantitative proteomics reveals a role for epigenetic reprogramming during human monocyte differentiation |
| Q38852070 | ROS1 fusions in cancer: a review |
| Q34734941 | Reassessment of risk genotypes (GRN, TMEM106B, and ABCC9 variants) associated with hippocampal sclerosis of aging pathology |
| Q33888606 | Regulated intramembrane proteolysis of the frontotemporal lobar degeneration risk factor, TMEM106B, by signal peptide peptidase-like 2a (SPPL2a). |
| Q39063017 | Subcellular Trafficking of Mammalian Lysosomal Proteins: An Extended View |
| Q41644307 | TDP-43 loss of function inhibits endosomal trafficking and alters trophic signaling in neurons |
| Q33746240 | TMEM106B expression is reduced in Alzheimer's disease brains |
| Q37730909 | TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions |
| Q37154601 | TMEM106B p.T185S regulates TMEM106B protein levels: implications for frontotemporal dementia |
| Q37621660 | TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia |
| Q57454682 | TMEM106B, a risk factor for FTLD and aging, has an intrinsically disordered cytoplasmic domain |
| Q36247028 | TMEM106B, the risk gene for frontotemporal dementia, is regulated by the microRNA-132/212 cluster and affects progranulin pathways |
| Q91451096 | Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy |
| Q29465536 | The ALS/FTLD associated protein C9orf72 associates with SMCR8 and WDR41 to regulate the autophagy-lysosome pathway |
| Q24314869 | The FTLD risk factor TMEM106B and MAP6 control dendritic trafficking of lysosomes |
| Q42089594 | The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death |
| Q35153681 | The TMEM106B locus and TDP-43 pathology in older persons without FTLD |
| Q42962467 | The frontotemporal lobar degeneration risk factor, TMEM106B, regulates lysosomal morphology and function |
| Q24615201 | The genetics and neuropathology of frontotemporal lobar degeneration |
| Q56594618 | The lysosomal function of progranulin, a guardian against neurodegeneration |
| Q38797600 | TiME for TMEM106B |
| Q34311246 | Transmembrane protein 106A is silenced by promoter region hypermethylation and suppresses gastric cancer growth by inducing apoptosis |
| Q35894863 | Transmembrane protein 106a activates mouse peritoneal macrophages via the MAPK and NF-κB signaling pathways |
| Q38932474 | What we know about TMEM106B in neurodegeneration |
Search more.